Protective chemotherapy after breast cancer surgery should not be delayed

Protective chemotherapy after breast cancer surgery should not be delayed. Particularly in disease at stages 2. and 3. in patients with triple-negative and her2-positive breast cancer , starting within the first 30 days positively affects survival.
Most breast cancer patients begin protective chemotherapy after surgery to prevent recurrence. Prolonged postoperative recovery or adaptation to the next treatment often delays chemotherapy.
A study in 2006 suggested chemotherapy could be delayed up to 12 weeks, but this did not fully convince oncologists because 12 weeks is long for protective treatment. Removing the main tumor may scientifically plausibly accelerate growth of invisible dispersed cancer cells, or micrometastases. Protective therapy aims to eliminate them and reduce recurrence. The latest study answered this important question convincingly.
The research found that beginning treatment to eliminate invisible cells and reduce recurrence as soon as possible after surgery benefits patients. Delay particularly harms high-risk or stage II and III. patients and increases recurrence risk, an important finding.
Data compared the first 30 days with after 60 days. Those treated within 30 days showed significantly reduced survival and recurrence risk. Particularly for stage II and III. disease and more aggressive HER2-positive and triple-negative groups, beginning chemotherapy within the first 1 month is highly valuable information. I advise patients and colleagues to prepare stage II. and III. patients with her2-positive or triple-negative tumors to begin protective (adjuvant) therapy within the first 1 month and plan accordingly.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.